Glonghui May 27 丨 Fosun Pharma (600196)(02196jackpotcitycasino.HK) issued an announcementjackpotcitycasinoThe drug registration application for norepinephrine bitartrate injection (hereinafter referred to as the "new drug") independently developed by the company's holding subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. was recently accepted by the State Food and Drug Administration.

This new drug is a chemical independently developed by the group and is intended to increase the blood pressure of adult patients with severe and acute hypotension.

As of April 2024, the Group's cumulative R & D investment in this new drug at this stage is approximately RMB 3.82 million (unaudited).

As of the date of this announcement, norepinephrine bitartrate injection that has been approved for marketing in China (excluding Hong Kong, Macao and Taiwan, the same below) mainly includes Yuanda Pharmaceutical (China) Co., Ltd., Xi'an Lijun Pharmaceutical Co., Ltd., Tianjin Jinyao Pharmaceutical Co., Ltd. Norepinephrine bitartrate injection, etc. According to the latest data from IQVIACHPA, sales of norepinephrine bitartrate injection in China in 2023 will be approximately RMB 1.967 billion.